AR041740A1 - Derivados de dihidropirimido [4,5-d] pirimidona sustituida por amino. metodo de obtencion y su uso como inhibidor de proteinquinasas - Google Patents
Derivados de dihidropirimido [4,5-d] pirimidona sustituida por amino. metodo de obtencion y su uso como inhibidor de proteinquinasasInfo
- Publication number
- AR041740A1 AR041740A1 ARP030104001A ARP030104001A AR041740A1 AR 041740 A1 AR041740 A1 AR 041740A1 AR P030104001 A ARP030104001 A AR P030104001A AR P030104001 A ARP030104001 A AR P030104001A AR 041740 A1 AR041740 A1 AR 041740A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cyano
- hydrogen
- group
- amino
- Prior art date
Links
- -1 AMINO Chemical class 0.000 title abstract 6
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 19
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 150000002431 hydrogen Chemical class 0.000 abstract 6
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000004043 oxo group Chemical group O=* 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 2
- 125000004442 acylamino group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se describe compuestos de la fórmula (1) Un proceso para la fabricación, medicamentos que los contienen y la fabricación de los mismos así como el uso de estos compuestos en calidad de agentes farmacéuticamente activos. Dichos compuestos despliegan actividad de inhibidores de proteinocinasas, en particular inhibidores de tirosinacinasas del grupo src, y por ello pueden ser útiles para el tratamiento de enfermedades medidas por dichas tirosinacinasas. Reivindicación 1: Un compuesto de la fórmula (1) en la que R1 significa hidrógeno o alquilo, cicloalquilo, arilo, heteroarilo, arilalquilo, heteroarilalquilo, todos ellos están eventualmente sustituidos; R2 significa halógeno, ciano, CF3; R3 con independencia de su aparición es halógeno, hidroxi, ciano, nitro, amino, acilamino, -CONH2, -SO2NH2, -S(O)m-alquilo, -NH-alquilo, -N(alquilo)2, -CONH(alquilo), -CON(alquilo)2, -SO2NH(alquilo), -SO2N(alquilo)2, o alquilo, alcoxi, alcoxialquilo, todos ellos están eventualmente sustituidos; R4 significa hidrógeno, alquilo, alcoxi, ciano; y A es un grupo de las fórmulas (A-1), (A-2), (A-3), (A-4), (A-5), o (A-6) R5 es hidrógeno, halógeno, hidroxi, ciano, amino, acilamino, alquilo, alcoxi, alcoxialquilo, -CONH2, -SO2NH2, -S(O)m-alquilo, -NH-alquilo, -N(alquilo)2, -CONH(alquilo), -CON(alquilo)2, -SO2NH(alquilo), -SO2N(alquilo)2; R6, R6' significan con independencia entre sí hidrógeno, alquilo u oxo; R7 es hidrógeno, acilo, alcoxicarbonilo, alcoxialquilo; o alquilo que está eventualmente sustituido con hidroxi, ciano, -S(O)m-alquilo, amino, -NH-alquilo o -N(alquilo)2; R8, R8' significan con independencia entre sí hidrógeno, oxo, alcoxi, alcoxialquilo; o alquilo eventualmente sustituido con hidroxi, ciano, pirrolidin-1-ilo, morfolino, piperazin-1-ilo, 4-alquil-piperazin-1-ilo, piperidin-1-ilo, -S(O)m-alquilo, o un grupo NR9R9', en el que R9 y R9' son con independencia entre sí hidrógeno, alquilo o cicloalquilo; X es oxígeno o S(O)m; la línea de trazo discontinuo es un segundo enlace químico opcional; n es 0, 1 ó 2; m es 0, 1 ó 2; p es 0, 1 ó 2; y sales farmacéuticamente aceptables o N-óxidos de los mismos; con la condición de que si R8 y R8' significan un grupo oxo, entonces este grupo oxo no sea adyacente de un grupo S(O)m.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02024573 | 2002-11-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR041740A1 true AR041740A1 (es) | 2005-05-26 |
Family
ID=32116230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030104001A AR041740A1 (es) | 2002-11-04 | 2003-10-31 | Derivados de dihidropirimido [4,5-d] pirimidona sustituida por amino. metodo de obtencion y su uso como inhibidor de proteinquinasas |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7091345B2 (es) |
| EP (1) | EP1560831A1 (es) |
| JP (1) | JP2006506408A (es) |
| KR (1) | KR100755770B1 (es) |
| CN (1) | CN1711265A (es) |
| AR (1) | AR041740A1 (es) |
| AU (1) | AU2003287982A1 (es) |
| BR (1) | BR0315988A (es) |
| CA (1) | CA2502477A1 (es) |
| GT (1) | GT200300240A (es) |
| MX (1) | MXPA05004212A (es) |
| PA (1) | PA8587101A1 (es) |
| PE (1) | PE20040593A1 (es) |
| PL (1) | PL377239A1 (es) |
| RU (1) | RU2005117342A (es) |
| TW (1) | TW200413381A (es) |
| UY (1) | UY28059A1 (es) |
| WO (1) | WO2004041823A1 (es) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2372028T3 (es) * | 2000-10-23 | 2012-01-13 | Glaxosmithkline Llc | Nuevo compuesto de 8h-pirido[2,3-d]pirimidin-7-ona trisustituida para el tratamiento de enfermedades mediadas por la csbp/p38 quinasa. |
| EP1651648A4 (en) * | 2003-07-29 | 2009-09-02 | Irm Llc | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS |
| FR2873118B1 (fr) * | 2004-07-15 | 2007-11-23 | Sanofi Synthelabo | Derives de pyrido-pyrimidine, leur application en therapeutique |
| BRPI0514750A (pt) * | 2004-08-31 | 2008-06-24 | Hoffmann La Roche | derivados amida de 7-amino-3-fenil-diidropirimido[4, 5-d]pirimidinonas, sua fabricação e uso como inibidores de proteìna cinase |
| ATE425166T1 (de) * | 2004-08-31 | 2009-03-15 | Hoffmann La Roche | Amidderivate von 3-phenyldihydropyrimidoä4,5- düpyrimidinonen, deren herstellung und verwendung als pharmazeutische mittel |
| MY145343A (en) * | 2005-03-25 | 2012-01-31 | Glaxo Group Ltd | Novel compounds |
| MX2007012951A (es) * | 2005-03-25 | 2008-01-11 | Glaxo Group Ltd | Procedimiento para preparar derivados de pirido[2,3-d] pirimidin-7-ona y 3,4-dihidropirimidino[4,5-d]pirimidin-2(1h)-ona. |
| ES2329419T3 (es) | 2006-01-31 | 2009-11-25 | F. Hoffmann-La Roche Ag | 7h-pirido(3,4-d)pirimidin-8-onas, su preparacion y uso como inhibidores de proteinas cinasas. |
| US7939557B2 (en) * | 2006-04-20 | 2011-05-10 | Nova Southeastern University | Vascular endothelial receptor specific inhibitors |
| BRPI0711628A2 (pt) * | 2006-05-15 | 2011-12-06 | Irm Llc | composto, composição farmacêutica, uso e processo para preparação do composto |
| SI2168966T1 (sl) * | 2007-06-15 | 2017-03-31 | Msd K.K. | Derivat biciklo anilina |
| TW200938542A (en) | 2008-02-01 | 2009-09-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
| JP5535931B2 (ja) | 2008-10-27 | 2014-07-02 | 武田薬品工業株式会社 | 二環性化合物 |
| US8507505B2 (en) | 2008-12-12 | 2013-08-13 | Msd K.K. | Dihydropyrazolopyrimidinone derivative |
| WO2010067888A1 (en) | 2008-12-12 | 2010-06-17 | Banyu Pharmaceutical Co.,Ltd. | Dihydropyrimidopyrimidine derivatives |
| CN102574847A (zh) | 2009-07-30 | 2012-07-11 | Irm责任有限公司 | 作为syk激酶抑制剂的化合物和组合物 |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| ES2984771T3 (es) | 2012-06-13 | 2024-10-31 | Incyte Holdings Corp | Compuestos tricíclicos sustituidos como inhibidores de FGFR |
| SG10201610869TA (en) | 2012-06-26 | 2017-02-27 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalacti |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| CN102816164A (zh) * | 2012-08-31 | 2012-12-12 | 北京理工大学 | 一种合成7-氨基-2,3-二氢嘧啶[4,5-d]嘧啶-4(1H)-酮的方法 |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| US9321786B2 (en) | 2013-03-15 | 2016-04-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| ES2892423T3 (es) | 2013-03-15 | 2022-02-04 | Celgene Car Llc | Compuestos de heteroarilo y usos de los mismos |
| EP2968337B1 (en) | 2013-03-15 | 2021-07-21 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
| DK2986610T5 (en) | 2013-04-19 | 2018-12-10 | Incyte Holdings Corp | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| PE20171514A1 (es) | 2015-02-20 | 2017-10-20 | Incyte Corp | Heterociclos biciclicos como inhibidores de fgfr |
| WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
| CN108815167B (zh) * | 2017-05-24 | 2021-04-13 | 四川晶华生物科技有限公司 | 一种化合物在制备治疗肿瘤的药物中的用途 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| BR112020022392A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | formas sólidas de um inibidor de fgfr e processos para preparação das mesmas |
| CR20200591A (es) | 2018-05-04 | 2021-03-31 | Incyte Corp | Sales de un inhibidor de fgfr |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CN115835908A (zh) | 2019-10-14 | 2023-03-21 | 因赛特公司 | 作为fgfr抑制剂的双环杂环 |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| JP2023505257A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤の誘導体 |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0084822B1 (de) | 1982-01-27 | 1986-01-08 | Schering Aktiengesellschaft | Diphosphonsäure-Derivate und diese enthaltende pharmazeutische Präparate |
| DE3365492D1 (en) | 1982-01-27 | 1986-10-02 | Schering Ag | Diphosphonic acid derivatives and pharmaceutical preparations containing them |
| DE3203308A1 (de) | 1982-01-27 | 1983-07-28 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Diphosphonsaeure-derivate und diese enthaltende pharmazeutische praeparate |
| DE3428524A1 (de) | 1984-08-02 | 1986-02-13 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| IL77243A (en) | 1984-12-21 | 1996-11-14 | Procter & Gamble | Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds |
| US4687768A (en) | 1984-12-21 | 1987-08-18 | The Procter & Gamble Company | Certain hexahydroindan-2,2-diphosphonic acids useful in treating diseases associated with abnormal calcium and phosphate metabolism |
| JPH08502287A (ja) | 1992-10-09 | 1996-03-12 | ジ・アップジョン・カンパニー | 抗炎症剤としてのピリミジンビスホスホン酸エステルおよび（アルコキシメチルホスフィニル）アルキルホスホン酸 |
| SE9402001D0 (sv) | 1994-06-09 | 1994-06-09 | Leiras Oy | Pyridylbisphosphonates for use as a therapeutical agent |
| ATE402177T1 (de) | 1998-05-26 | 2008-08-15 | Warner Lambert Co | Bicyclische pyrimidine und bicyclische 3,4- dihydropyrimidine als inhibitoren der zellvermehrung |
| EP1123295B1 (en) | 1998-10-23 | 2004-09-29 | F. Hoffmann-La Roche Ag | Bicyclic nitrogen heterocycles |
| CZ20021744A3 (cs) | 1999-10-21 | 2002-08-14 | F. Hoffmann-La Roche Ag | Bicyklické dusíkové heterocykly substituované heteroalkylaminoskupinou jako inhibitory P38 proteinkinázy |
| TR200201058T2 (tr) | 1999-10-21 | 2002-07-22 | F.Hoffmann-La Roche Ag | P38 protein kinaz inhibitörleri olarak, alkilaminoyla ornatılmış bisiklik, azotlu heterosikller |
| CA2394650A1 (en) | 1999-12-17 | 2001-06-21 | Chi B. Vu | Novel heterocycles |
-
2003
- 2003-10-29 TW TW092130056A patent/TW200413381A/zh unknown
- 2003-10-30 US US10/697,543 patent/US7091345B2/en not_active Expired - Fee Related
- 2003-10-30 PA PA20038587101A patent/PA8587101A1/es unknown
- 2003-10-31 UY UY28059A patent/UY28059A1/es not_active Application Discontinuation
- 2003-10-31 AR ARP030104001A patent/AR041740A1/es not_active Application Discontinuation
- 2003-10-31 PE PE2003001103A patent/PE20040593A1/es not_active Application Discontinuation
- 2003-11-03 RU RU2005117342/04A patent/RU2005117342A/ru not_active Application Discontinuation
- 2003-11-03 CA CA002502477A patent/CA2502477A1/en not_active Abandoned
- 2003-11-03 AU AU2003287982A patent/AU2003287982A1/en not_active Abandoned
- 2003-11-03 KR KR1020057007978A patent/KR100755770B1/ko not_active IP Right Cessation
- 2003-11-03 GT GT200300240A patent/GT200300240A/es unknown
- 2003-11-03 MX MXPA05004212A patent/MXPA05004212A/es active IP Right Grant
- 2003-11-03 WO PCT/EP2003/012203 patent/WO2004041823A1/en active Application Filing
- 2003-11-03 JP JP2004548850A patent/JP2006506408A/ja active Pending
- 2003-11-03 BR BR0315988-4A patent/BR0315988A/pt not_active IP Right Cessation
- 2003-11-03 EP EP03779831A patent/EP1560831A1/en not_active Withdrawn
- 2003-11-03 CN CNA200380102849XA patent/CN1711265A/zh active Pending
- 2003-11-03 PL PL377239A patent/PL377239A1/pl not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200413381A (en) | 2004-08-01 |
| US20040087600A1 (en) | 2004-05-06 |
| MXPA05004212A (es) | 2005-06-08 |
| CN1711265A (zh) | 2005-12-21 |
| WO2004041823A1 (en) | 2004-05-21 |
| PE20040593A1 (es) | 2004-09-09 |
| KR20050067433A (ko) | 2005-07-01 |
| PA8587101A1 (es) | 2004-09-16 |
| JP2006506408A (ja) | 2006-02-23 |
| PL377239A1 (pl) | 2006-01-23 |
| KR100755770B1 (ko) | 2007-09-05 |
| RU2005117342A (ru) | 2006-01-20 |
| EP1560831A1 (en) | 2005-08-10 |
| US7091345B2 (en) | 2006-08-15 |
| UY28059A1 (es) | 2004-04-30 |
| BR0315988A (pt) | 2005-09-20 |
| CA2502477A1 (en) | 2004-05-21 |
| GT200300240A (es) | 2004-09-02 |
| AU2003287982A1 (en) | 2004-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR041740A1 (es) | Derivados de dihidropirimido [4,5-d] pirimidona sustituida por amino. metodo de obtencion y su uso como inhibidor de proteinquinasas | |
| PE20230825A1 (es) | Inhibidores de kras triciclicos fusionados | |
| CA3004372C (en) | Pyrimidine derivative and use thereof | |
| PE20221905A1 (es) | Aminas biciclicas como inhibidoras de la cdk2 | |
| AR067599A1 (es) | Derivados de indazol sustituido activos como inhibidores de quinasa | |
| AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
| CN103958475B (zh) | 杂芳基异羟肟酸衍生物及其在治疗、减轻或预防病毒疾病中的用途 | |
| NO20063748L (no) | Kinolinderivater og anvendelse derav som mykobakterielle inhibitorer | |
| NO20063597L (no) | Acetylinske piperazinforbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister | |
| AR052902A1 (es) | Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa | |
| NO20071067L (no) | Nye cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer. | |
| NO20063468L (no) | Triazolforbindelser og deres anvendelse som metabotrofe glutamatreseptorantagonister | |
| NO20063821L (no) | Kinolinderivater for anvendelse som mykobakterielle inhibitorer | |
| NO20051826L (no) | Heterosyklisk substituerte piperaziner for behandling av schizofreni | |
| AR035815A1 (es) | Derivados de piperidina, un proceso para su preparacion, composiciones y combinaciones farmacéuticas que comprenden a dichos derivados | |
| AR051202A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
| JP6033873B2 (ja) | ピリミジン−４−オン誘導体及びウイルス性疾患の治療、改善又は予防におけるその使用 | |
| AR056886A1 (es) | Compuestos de pirrolopiridina sustituida inhibidores de quinasas, composiciones farmaceuticas que los contienen y usos en el tratamiento del cancer | |
| AR051092A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa | |
| NO20092050L (no) | Nye sulfonamidderivater som bradykininantagonister | |
| AR051094A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
| NO20063469L (no) | Polyeheterosykliske forbindelser og deres anvendelse som metabotrofe glutamat reseptorantagonister | |
| ECSP034475A (es) | Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1 | |
| AR051294A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
| MX2022000854A (es) | Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |